From the publishers of JADPRO

MPN Resource Center

Advertisement

An epidemiological study of the cardiovascular health and thrombotic risk profiles of patients with myeloproliferative neoplasms in primary care across the United Kingdom

Last Updated: Tuesday, July 6, 2021

Retrospective data presented during the 2021 European Hematology Association Virtual Congress suggests that 11.1% to 22.1% of MPN patients in the United Kingdom did not receive the appropriate medications for the management of comorbidities associated with thrombotic risk, including hypertension, dyslipidemia, and diabetes.

2021 European Hematology Association Virtual Congress (Abstract)
Advertisement
News & Literature Highlights
Advertisement
Advertisement